Effects of Early and Late Intervention with Epoetin α on Left Ventricular Mass among Patients with Chronic Kidney Disease (Stage 3 or 4): Results of a Randomized Clinical Trial

Journal of the American Society of Nephrology

Volumn 15, Issue 1, 2004, Pages 148-156

  Roger, Simon D ^a   McMahon, Lawrence P ^b   Clarkson, Anthony ^c   Disney, Alex ^d   Harris, David ^e   Hawley, Carmel ^f   Healy, Helen ^g   Kerr, Peter ^h   Lynn, Kelvin ⁱ   Parnham, Alan ^j   Pascoe, Roess ^k   Voss, David ^l   Walker, Robert ^m   Levin, Adeera ⁿ  

^a GOSFORD HOSPITAL   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d Queen Elizabeth II Hospital   (Australia)

^e WESTMEAD HOSPITAL   (Australia)

^f PRINCESS ALEXANDRA HOSPITAL   (Australia)

^g ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^h MONASH MEDICAL CENTRE   (Australia)

ⁱ CHRISTCHURCH HOSPITAL   (New Zealand)

^j GOLD COAST UNIVERSITY HOSPITAL   (Australia)

^k Hearts 1st   (Australia)

^l MIDDLEMORE HOSPITAL   (New Zealand)

^m Department of Renal Medicine ^*  (New Zealand)

ⁿ ST PAUL S HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; IRON POLYMALTOSE; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; CHRONOLOGY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

EID: 9144239992     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000102471.89084.8B     Document Type: Article

References (49)

1. Hsu CY, McCulloch CE, Curhan GC: Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: Results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 13: 504-510, 2002
2. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, Schneider KA: Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: Results from the hypertension detection and follow-up program. Hypertension 13: 180-193, 1989
3. Matts JP, Karnegis JN, Campos CT, Fitch LL, Johnson JW, Buchwald H: Serum creatinine as an independent predictor of coronary heart disease mortality in normotensive survivors of myocardial infarction. J Fam Pract 36: 497-503, 1993
4. Pahor M, Psaty BM, Furberg CD: New evidence on the prevention of cardiovascular events in hypertensive patients with type 2 diabetes. J Cardiovasc Pharmacol 32[Suppl 2]: S18-S23, 1998
5. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW: The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 35: 681-689, 2000
6. Shlipak MG, Simon JA, Grady D, Lin F, Wenger NK, Furberg CD, Heart and Estrogen/Progestin Replacement Study (HERS) Investigators: Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. J Am Coll Cardiol 38: 705-711, 2001
7. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 134: 629-636, 2001
8. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, Zanchetti A: Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol 12: 218-225, 2001
9. Schillaci G, Reboldi G, Verdecchia P: High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. Arch Intern Med 161: 886-891, 2001
10. Al Suwaidi J, Reddan DN, Williams K, Pieper KS, Harrington RA, Califf RM, Granger CB, Ohman EM, Holmes DR Jr, GUSTO-IIb, GUSTO-III, PURSUIT, PARAGON-A Investigators: Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 106: 974-980, 2002
11. Wannamethee SG, Shaper AG, Perry IJ: Serum creatinine concentration and risk of cardiovascular disease: A possible marker for increased risk of stroke. Stroke 28: 557-563, 1997
12. Fink J, Blahut S, Reddy M, Light P: Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 37: 348-355, 2001
13. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D: Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 56: 2214-2219, 1999
14. Muntner P, Coresh J, Klag MJ, Whelton PK, Perneger TV: History of myocardial infarction and stroke among incident end-stage renal disease cases and population-based controls: An analysis of shared risk factors. Am J Kidney Dis 40: 323-330, 2002
15. Muntner P, He J, Hamm L, Loria C, Whelton PK: Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 13: 745-753, 2002
16. United States Renal Data System: Annual Data Report 2002, available at http://www.usrds.org
17. McDonald SP, Russ GR (eds): ANZDATA Registry Report, 2002. Available at: www.nephrology.edu.au/renal/anzdata/index.htm
18. Silberberg JS, Barre PE, Prichard SS, Sniderman AD: Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36: 286-290, 1989
19. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32[Suppl 3]: S112-S119, 1998
20. Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, Coyle D, Fine A, Handa P, Kingma I, Lau CY, Levin A, Mendelssohn D, Muirhead N, Murphy B, Plante RK, Posen G, Wells GA: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58: 1325-1335, 2000
21. Ma JZ, Ebben J, Xia H, Collins AJ: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10: 610-619, 1999
22. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: 607-617, 1998
23. National Kidney Foundation: K/DOQI Guidelines, available at http://www.kidney.org/professionals/doqi
24. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47: 186-192, 1995
25. Levin A, Singer J, Thompson CR, Ross H, Lewis M: Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 27: 347-354, 1996
26. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE: Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 11: 912-916, 2000
27. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41, 1976
28. Oh JK, Seward JB, Tajik AJ. The Echo Manual, 1st Ed., Boston, Little, Brown, 1994
29. Sahn DJ, DeMaria A, Kisslo J, Weyman A: Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 58: 1072-1083, 1978
30. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N: Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 57: 450-458, 1986
31. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux RB, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I, Silverman NH, Tajik AJ: Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 2: 358-367, 1989
32. Hammond IW, Devereux RB, Alderman MH: The prevalence and correlation of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension. J Am Coll Cardiol 7: 639-650, 1986
33. Agabiti-Rosei E, Ambrosioni E, Dal Palu C, Muiesan ML, Zanchetti A, RACE Study Group: ACE inhibitor ramipril is more effective than the β-blocker atenolol in reducing left ventricular hypertrophy in hypertension: Results of the RACE (Ramipril Cardioprotective Evaluation) study. J Hypertens 13: 1325-1332, 1995
34. Levin A, Djurdjev O, Barrett B, Burgess E, Carlisle E, Ethier J, Jindal K, Mendelssohn D, Tobe S, Singer J, Thompson C: Cardiovascular disease in patients with chronic kidney disease: Getting to the heart of the matter. Am J Kidney Dis 38: 1398-1407, 2001
35. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O: Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 34: 125-134, 1999
36. Portoles J, Torralbo A, Martin P, Rodrigo J, Herrero JA, Barrientos A: Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 29: 541-548, 1997
37. Hayashi T, Suzuki A, Shoji T, Togawa M, Okada N, Tsubakihara Y, Imai E, Hori M: Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 35: 250-256, 2000
38. McMahon LP, Johns JA, McKenzie A, Austin M, Fowler R, Dawborn JK: Haemodynamic changes and physical performance at comparative levels of haemoglobin after long-term treatment with recombinant erythropoietin. Nephrol Dial Transplant 7: 1199-1206, 1992
39. Roth D, Smith RD, Schulman G, Steinman TI, Hatch FE, Rudnick MR, Sloand JA, Freedman BI, Williams WW Jr, Shadur CA, et al.: Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 24: 777-784, 1994
40. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, Schwartz D, Yachnin T, Steinbruch S, Shapira I, Laniado S, Iaina A: The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: A randomized controlled study. J Am Coll Cardiol 37: 1775-1780, 2001
41. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS: Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107: 294-299, 2003
42. Benz RL, Pressman MR, Hovick ET, Peterson DD: A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (the SLEEPO study). Am J Kidney Dis 34: 1089-1095, 1999
43. Grimm G, Stockenhuber F, Schneeweiss B, Madl C, Zeitlhofer J, Schneider B: Improvement of brain function in hemodialysis patients treated with erythropoietin. Kidney Int 38: 480-486, 1990
44. McMahon LP, McKenna MJ, Sangkabutra T, Mason K, Sostaric S, Skinner SL, Burge C, Murphy B, Crankshaw D: Physical performance and associated electrolyte changes after haemoglobin normalization: A comparative study in haemodialysis patients. Nephrol Dial Transplant 14: 1182-1187, 1999
45. McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ: Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 15: 1425-1430, 2000
46. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrabano F: Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients: Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol 11: 335-342, 2000
47. Raine AE: Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: Implications of erythropoietin therapy. Lancet 1: 97-100, 1988
48. Raine AE, Roger SD: Effects of erythropoietin on blood pressure. Am J Kidney Dis 18[Suppl 1]: 76-83, 1991
49. Schrier R, McFann K, Johnson A, Chapman A, Edelstein C, Brosnahan G, Ecder T, Tison L: Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: Results of a seven-year prospective randomized study. J Am Soc Nephrol 13: 1733-1739, 2002